DK3309150T3 - (r)-3-(4'-(2-(2-methylpyrrolidin-1-yl)ethyl)biphenyl-4-yl)propansyre som histamin-h3-receptormodulatorer til behandlingen af kognitive lidelser - Google Patents

(r)-3-(4'-(2-(2-methylpyrrolidin-1-yl)ethyl)biphenyl-4-yl)propansyre som histamin-h3-receptormodulatorer til behandlingen af kognitive lidelser Download PDF

Info

Publication number
DK3309150T3
DK3309150T3 DK17186099.2T DK17186099T DK3309150T3 DK 3309150 T3 DK3309150 T3 DK 3309150T3 DK 17186099 T DK17186099 T DK 17186099T DK 3309150 T3 DK3309150 T3 DK 3309150T3
Authority
DK
Denmark
Prior art keywords
histamin
methylpyrrolidin
biphenyl
ethyl
treatment
Prior art date
Application number
DK17186099.2T
Other languages
English (en)
Inventor
Jonathan A Covel
Albert S Ren
Graeme Semple
Thuy-Anh Tran
Yifeng Xiong
Wei Zheng
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Application granted granted Critical
Publication of DK3309150T3 publication Critical patent/DK3309150T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
DK17186099.2T 2013-01-09 2014-01-08 (r)-3-(4'-(2-(2-methylpyrrolidin-1-yl)ethyl)biphenyl-4-yl)propansyre som histamin-h3-receptormodulatorer til behandlingen af kognitive lidelser DK3309150T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361750475P 2013-01-09 2013-01-09
EP14701137.3A EP2943473B1 (en) 2013-01-09 2014-01-08 Biphenyl-ethyl-pyrrolidine derivatives as histamine h3 receptor modulators for the treatment of cognitive disorders

Publications (1)

Publication Number Publication Date
DK3309150T3 true DK3309150T3 (da) 2021-08-30

Family

ID=50000114

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17186099.2T DK3309150T3 (da) 2013-01-09 2014-01-08 (r)-3-(4'-(2-(2-methylpyrrolidin-1-yl)ethyl)biphenyl-4-yl)propansyre som histamin-h3-receptormodulatorer til behandlingen af kognitive lidelser

Country Status (9)

Country Link
US (1) US9365511B2 (da)
EP (3) EP3309150B1 (da)
JP (1) JP6253668B2 (da)
CN (1) CN105263914B (da)
DK (1) DK3309150T3 (da)
ES (2) ES2647965T3 (da)
LT (1) LT3309150T (da)
PT (1) PT3309150T (da)
WO (1) WO2014110103A1 (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3391886A1 (en) 2017-04-19 2018-10-24 Novartis AG The use of a h3r inverse agonist for the treatment of shift work disorder
EP4251148A1 (en) 2020-11-27 2023-10-04 Richter Gedeon Nyrt. Histamine h3 receptor antagonists/inverse agonists for the treatment of autism spectrum disorder
KR102710574B1 (ko) * 2022-03-28 2024-09-27 주식회사 비엔에이치리서치 약물의 전기생리학적 스크리닝 방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217986A (en) 1992-03-26 1993-06-08 Harbor Branch Oceanographic Institution, Inc. Anti-allergy agent
US5352707A (en) 1992-03-26 1994-10-04 Harbor Branch Oceanographic Institution, Inc. Method for treating airway congestion
US5869479A (en) 1997-08-14 1999-02-09 Schering Corporation Treatment of upper airway allergic responses
WO2002074758A2 (en) * 2001-03-16 2002-09-26 Abbott Laboratories Novel amines as histamine-3 receptor ligands and their therapeutic applications
PL376751A1 (pl) * 2002-11-12 2006-01-09 Abbott Laboratories Bicykliczne podstawione aminy jako ligandy receptora histaminowego-3
US20050245543A1 (en) * 2004-04-30 2005-11-03 Pfizer Inc Histamine-3 receptor antagonists
PL1747210T3 (pl) * 2004-05-07 2010-11-30 Warner Lambert Co Pochodne 3- lub 4-monopodstawionego fenolu i tiofenolu użyteczne jako ligandy H3
US20060014733A1 (en) * 2004-07-19 2006-01-19 Pfizer Inc Histamine-3 agonists and antagonists
WO2008005338A1 (en) * 2006-06-29 2008-01-10 Arena Pharmaceuticals, Inc. Modulators of the histamine h3-receptor useful for the treatment of disorders related thereto
TW200823204A (en) * 2006-10-17 2008-06-01 Arena Pharm Inc Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine H3-receptor useful for the treatment of disorders related thereto
WO2009058300A1 (en) * 2007-10-30 2009-05-07 Arena Pharmaceuticals, Inc. Biphenyl derivatives as modulators of the histamine-h3 receptor useful for the treatment of disorders related thereto

Also Published As

Publication number Publication date
CN105263914A (zh) 2016-01-20
US20150353488A1 (en) 2015-12-10
PT3309150T (pt) 2021-08-31
EP2943473A1 (en) 2015-11-18
JP6253668B2 (ja) 2017-12-27
LT3309150T (lt) 2021-10-25
US9365511B2 (en) 2016-06-14
EP3309150B1 (en) 2021-06-02
EP2943473B1 (en) 2017-08-23
HK1253019A1 (en) 2019-06-06
JP2016504388A (ja) 2016-02-12
CN105263914B (zh) 2017-10-27
ES2647965T3 (es) 2017-12-27
EP3309150A1 (en) 2018-04-18
HK1219953A1 (zh) 2017-04-21
EP3889141A1 (en) 2021-10-06
ES2886914T3 (es) 2021-12-21
WO2014110103A1 (en) 2014-07-17

Similar Documents

Publication Publication Date Title
MA55046A (fr) Utilisation de dérivés d'indole n-substitués comme modulateurs des récepteurs des pge2
CY2024024I2 (el) Υδροχλωρικα αλατα ν-(κυανομεθυλ)-4-(2-(4- μορφολινοφαινυλαμινο)πυριμιδιν-4-υλ)βενζαμιδιου
EP2812004A4 (en) COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCLE ATROPHY
DK3134386T3 (da) Isoindolin-1-on-derivater med kolinerg muscarin-m1-receptor-positiv allosterisk modulatoraktivitet til behandling af alzheimers sygdom
DK2968218T3 (da) Kombination til behandling af parkinsons sygdom
MA42592A (fr) Utilisation de dérivés de 2-(pyrazolopyridin-3-yl) pyrimidine en tant qu'inhibiteurs de jak
DK3333161T3 (da) 2-(2,4,5-substitueret anilin)-pyrimidinderivater som egfr-modulatorer, der er anvendelige til behandling af cancer
DK3811943T3 (da) Forbindelse til anvendelse til behandling af øjenlidelser
DK3119397T3 (da) Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser
EP2828247A4 (en) COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCLE ATROPHY
EP2819519A4 (en) COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCLE ATROPHY
EP3359164A4 (en) COMPOUNDS AND METHOD FOR MODULATING ANGIOTENSINOGENEXPRESSION
PT3220916T (pt) Método para tratamento de cancro com n-((4,6-dimetil-2-oxo-1,2-di-hidropiridina-3-il)metil)-5-(etil(tetrahidro-2h-piran-4-il) amino)-4-metil-4'-(morfolinometil)-[1,1'-bifenilo]-3-carboxamida
EP3013345A4 (en) COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCLE ATROPHY
DK3305317T3 (da) Forbindelser til behandling af neuropsykiatriske forstyrrelser
DK3624796T3 (da) Pyrrolopyridin.anilinforbindelser til behandling af hudlidelse
DK2987791T3 (da) 3-(4-(Benzyloxy)phenyl)hex-4-insyre-derivat, egnet til forebyggelse og behandling af metaboliske sygdomme
EA201790892A1 (ru) Кристаллические формы 5-хлор-n4-[2-(диметилфосфорил)фенил]-n2-{2-метокси-4-[4-(4-метилпиперазин-1-ил)пиперидин-1-ил]}пиримидин-2,4-диамина
DK2747763T3 (da) (bacterio-)chlorofyllfotosensibilisatorer til behandling af øjensygdomme og -lidelser
EP2694964A4 (en) HIGH-SPEED SCREENING FOR COMPOUNDS FOR MODULATING THE EXPRESSION OF CELLULAR MACROMOLECULES
DK3386991T3 (da) Polycykliske forbindelser som inhibitorer af bruton's tyrosinkinase
HUE040231T2 (hu) Máj X receptor (LXR) modulátorok bõrbetegségek, rendellenességek és állapotok kezelésére
EP2806876A4 (en) Proteasome activity enhancing compounds
DK3439661T3 (da) Fremgangsmåder til behandling af øjenlidelser
EP2906531A4 (en) COMPOUNDS FOR SYNTHESIS OF BENZAMIDE COMPOUNDS